The U.S. Department of Health and Human Services (HHS) has terminated significant grant funding totaling $766 million intended for Moderna’s late-stage development of prepandemic influenza mRNA vaccines, including a candidate targeting the highly concerning H5N1 avian influenza, commonly known as bird flu. The cancellation, confirmed via a Moderna news release, comes amidst ongoing and widespread H5N1 outbreaks across the United States, particularly impacting dairy cattle and poultry flocks, and with limited human cases reported globally.
Unpacking the Canceled Funding
The terminated grants represent a substantial withdrawal of federal support for a key vaccine development program aimed at bolstering the nation’s preparedness against potential influenza pandemics. Specifically, the cancellation affects two major awards: a $176 million grant initially awarded in July 2024, and a larger $590 million grant that was slated for January 2025. Both grants were channeled through the Rapid Response Partnership Vehicle (RRPV) Consortium, leveraging funding from the Biomedical Advanced Research and Development Authority (BARDA). BARDA is a critical component of the U.S. government’s preparedness strategy, tasked with developing and procuring countermeasures against public health emergencies, including pandemic influenza. The RRPV Consortium acts as a mechanism to accelerate the development and manufacturing of such countermeasures.
Decision Amidst Rising Bird Flu Concerns
The timing of HHS’s decision introduces considerable uncertainty into Moderna’s prepandemic influenza program. It coincides with a period of heightened alert regarding the H5N1 virus. While primarily affecting birds and mammals, the virus’s detection in livestock and a small number of human cases underscores the potential for zoonotic transmission and the importance of having ready vaccine candidates. The cancellation of funding for a vaccine specifically targeting H5 avian flu, among others, at this critical juncture raises questions about the path forward for preparedness efforts dependent on advanced vaccine technologies like mRNA platforms.
This decision by HHS, led by Secretary Robert F. Kennedy Jr., comes despite positive interim data from Moderna’s phase 1/2 clinical trial (NCT05972174) of its H5 avian flu vaccine candidate, mRNA-1018.
Moderna’s Program and Promising Data
Moderna’s efforts focused on developing mRNA-based vaccines, a technology rapidly advanced during the COVID-19 pandemic, for a range of influenza threats. The canceled grants were earmarked for the late-stage development phase, which typically involves large-scale clinical trials necessary for regulatory approval and preparation for potential mass production.
Central to this program was the H5 avian flu vaccine candidate, mRNA-1018. Moderna had been evaluating this candidate in a Phase 1/2 clinical trial, registered under the identifier NCT05972174. According to the company’s news release, interim data from this trial demonstrated encouraging results. The data reportedly showed a significant immune response among participants, indicating the vaccine’s potential to generate protective antibodies. Furthermore, the trial reported a tolerable safety profile, essential for any vaccine intended for widespread use. A specific data point highlighted was that 97.8% of participants achieved protective antibody titers, a key metric indicating a potentially effective immune response against the targeted H5 virus.
Company Response and Future Path
In response to the grant cancellations, Moderna’s CEO, Stéphane Bancel, issued a statement acknowledging the situation while emphasizing the positive clinical trial results. Mr. Bancel stated the company is “pleased with the trial results,” affirming the scientific promise demonstrated by the mRNA-1018 candidate and likely other vaccine candidates within the prepandemic flu program.
However, the termination of significant government funding necessitates a strategic pivot for the company. Mr. Bancel indicated that Moderna would explore “alternative paths for the program” following the funding cut. This could involve seeking alternative funding sources, potentially pursuing the program entirely with internal resources, or adjusting the scope and timeline of development.
Implications for Pandemic Preparedness
The withdrawal of federal funding for a late-stage mRNA pandemic influenza vaccine program underscores the complex and sometimes uncertain landscape of public-private partnerships in health security. While government funding, often channeled through entities like BARDA, is crucial for de-risking early-stage research and accelerating development of critical countermeasures that may not have immediate commercial markets, the continuation of such support can be subject to changing priorities or assessments.
The cancellation poses a challenge for maintaining momentum in developing advanced vaccine technologies specifically tailored for emerging influenza threats like H5N1. It highlights the potential vulnerability of key preparedness programs to shifts in funding priorities, even when clinical data indicates promise. The future of Moderna’s specific prepandemic influenza vaccine candidates now depends on the “alternative paths” the company can successfully navigate, potentially impacting the timeline for having a readily available mRNA vaccine should an H5N1 variant or other influenza strain gain the ability to spread efficiently among humans.
Conclusion
HHS’s cancellation of $766 million in grants for Moderna’s prepandemic influenza mRNA vaccine development marks a significant development in the field of public health preparedness. The decision withdraws substantial federal support for a program that had reported positive clinical trial data for its H5 avian flu candidate amidst growing concerns over widespread H5N1 outbreaks. While Moderna plans to seek alternative avenues to continue its program, the termination of BARDA-backed funding introduces uncertainty regarding the timeline and resources available for advancing these crucial vaccine candidates towards potential deployment. The event underscores the dynamic nature of government funding for pandemic preparedness and the challenges companies face in navigating the path from promising research to deployable public health tools.
